FOXL2 encodes a forkhead transcription factor that plays important roles in the ovary during development and in post-natal, adult life. Here, we focus on the clinical consequences of FOXL2 impairment in human disease. In line with other forkhead transcription factors, its constitutional genetic defects and a somatic mutation lead to developmental disease and cancer, respectively. More than 100 unique constitutional mutations and regulatory defects have been found in blepharophimosis syndrome (BPES), a complex eyelid malformation associated (type I) or not (type II) with premature ovarian failure (POF). In agreement with the BPES phenotype, FOXL2 is expressed in the developing eyelids and in fetal and adult ovaries. Two knock-out mice and at least one natural animal model, the Polled Intersex Syndrome goat, are known. They recapitulate the BPES phenotype and have provided many insights into the ovarian pathology. Only a few constitutional mutations have been described in nonsyndromic POF. Moreover, a recurrent somatic mutation p.C134W was found to be specific for adult ovarian granulo-sa cell tumors. Functional studies investigating the consequences of FOXL2 mutations or regulatory defects have shed light on the molecular pathogenesis of the aforementioned conditions, and contributed considerably to genotype-phenotype correlations. Recently, a conditional knock-out of Foxl2 in the mouse induced somatic transdifferentiation of ovary into testis in adult mice, suggesting that Foxl2 has an anti-testis function in the adult ovary. This changed our view on the ovary and testis as terminally differentiated organs in adult mammals. Finally, this might have potential implications for the understanding and treatment of frequent conditions such as POF and polycystic ovary syndrome.

Keywords:
FOXL2 mutation, BPES, POF, Adult GCT, Anti-testis action
1.
Lehmann OJ, Sowden JC, Carlsson P, Jordan T, Bhattacharya SS: Fox's in development and disease. Trends Genet 2003;19:339-344.
2.
Crisponi L, Deiana M, Loi A, et al: The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001;27:159-166.
3.
Cocquet J, Pailhoux E, Jaubert F, Servel N, Xia X, Pannetier M, De Baere E, Messiaen L, Cotinot C, Fellous M, Veitia RA: Evolution and expression of FOXL2. J Med Genet 2002;39:916-921.
4.
Cocquet J, De Baere E, Gareil M, Pannetier M, Xia X, Fellous M, Veitia RA: Structure, evolution and expression of the FOXL2 transcription unit. Cytogenet Genome Res 2003;101:206-211.
5.
Treier M, Gleiberman AS, O'Connell SM, Szeto DP, McMahon JA, McMahon AP, Rosenfeld MG: Multistep signaling requirements for pituitary organogenesis in vivo. Genes Dev 1998;12:1691-1704.
6.
Ellsworth BS, Egashira N, Haller JL, Butts DL, Cocquet J, Clay CM, Osamura RY, Camper SA: FOXL2 in the pituitary: molecular, genetic, and developmental analysis. Mol Endocrinol 2006;20:2796-2805.
7.
Decock CE, Claerhout I, Leroy BP, Kesteleyn P, Shah AD, De Baere E: Correction of the lower eyelid malpositioning in the blepharophimosis-ptosis-epicanthus inversus syndrome. Ophthal Plast Reconstr Surg 2011;27:368-370.
8.
Oley C, Baraitser M: Blepharophimosis, ptosis, epicanthus inversus syndrome (BPES syndrome). J Med Genet 1988;25:47-51.
9.
Zlotogora J, Sagi M, Cohen T: The blepharophimosis, ptosis, and epicanthus inversus syndrome: delineation of two types. Am J Hum Genet 1983;35:1020-1027.
10.
De Vos M, Devroey P, Fauser BC: Primary ovarian insufficiency. Lancet 2010;376:911-921.
11.
Fraser IS, Shearman RP, Smith A, Russell P: An association among blepharophimosis, resistant ovary syndrome, and true premature menopause. Fertil Steril 1988;50:747-751.
12.
Meduri G, Bachelot A, Duflos C, Bstandig B, Poirot C, Genestie C, Veitia R, De Baere E, Touraine P: FOXL2 mutations lead to different ovarian phenotypes in BPES patients: case report. Hum Reprod 2010;25:235-243.
13.
Goswami D, Conway GS: Premature ovarian failure. Hum Reprod Update 2005;11:391-410.
14.
Kalantaridou SN, Davis SR, Nelson LM: Premature ovarian failure. Endocrinol Metab Clin North Am 1998;27:989-1006.
15.
Donnez J, Dolmans MM: Preservation of fertility in females with haematological malignancy. Br J Haematol 2011;154:175-184.
16.
Donnez J, Martinez-Madrid B, Jadoul P, Van Langendonckt A, Demylle D, Dolmans MM: Ovarian tissue cryopreservation and transplantation: a review. Hum Reprod Update 2006;12:519-535.
17.
Tao T, Del Valle A: Human oocyte and ovarian tissue cryopreservation and its application. J Assist Reprod Genet 2008;25:287-296.
18.
Cobo A, Remohi J, Chang CC, Nagy ZP: Oocyte cryopreservation for donor egg banking. Reprod Biomed Online 2011;23:341-346.
19.
Beysen D, De Paepe A, Baere ED: FOXL2 mutations and genomic rearrangements in BPES. Hum Mutat 2009;30:158-169.
20.
De Baere E, Beysen D, Oley C, et al: FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation. Am J Hum Genet 2003;72:478-487.
21.
De Baere E, Dixon MJ, Small KW, et al: Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrate a genotype-phenotype correlation. Hum Mol Genet 2001;10:1591-1600.
22.
Caburet S, Demarez A, Moumne L, Fellous M, De Baere E, Veitia RA: A recurrent polyalanine expansion in the transcription factor FOXL2 induces extensive nuclear and cytoplasmic protein aggregation. J Med Genet 2004;41:932-936.
23.
Moumne L, Dipietromaria A, Batista F, Kocer A, Fellous M, Pailhoux E, Veitia RA: Differential aggregation and functional impairment induced by polyalanine expansions in FOXL2, a transcription factor involved in cranio-facial and ovarian development. Hum Mol Genet 2008;17:1010-1019.
24.
Beysen D, Moumne L, Veitia R, Peters H, Leroy BP, De Paepe A, De Baere E: Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation. Hum Mol Genet 2008;17:2030-2038.
25.
Dipietromaria A, Benayoun BA, Todeschini AL, Rivals I, Bazin C, Veitia RA: Towards a functional classification of pathogenic FOXL2 mutations using transactivation reporter systems. Hum Mol Genet 2009;18:3324-3333.
26.
Todeschini AL, Dipietromaria A, L'Hote D, Boucham FZ, Georges AB, Pandaranayaka PJ, Krishnaswamy S, Rivals I, Bazin C, Veitia RA: Mutational probing of the forkhead domain of the transcription factor FOXL2 provides insights into the pathogenicity of naturally occurring mutations. Hum Mol Genet 2011;20:3376-3385.
27.
Beysen D, Raes J, Leroy BP, et al: Deletions involving long-range conserved nongenic sequences upstream and downstream of FOXL2 as a novel disease-causing mechanism in blepharophimosis syndrome. Am J Hum Genet 2005;77:205-218.
28.
D'haene B, Nevado J, Pugeat M, et al: FOXL2 copy number changes in the molecular pathogenesis of BPES: unique cohort of 17 deletions. Hum Mutat 2010;31:E1332-E1347.
29.
Crisponi L, Uda M, Deiana M, Loi A, Nagaraja R, Chiappe F, Schlessinger D, Cao A, Pilia G: FOXL2 inactivation by a translocation 171 kb away: analysis of 500 kb of chromosome 3 for candidate long-range regulatory sequences. Genomics 2004;83:757-764.
30.
D'Haene B, Attanasio C, Beysen D, Dostie J, Lemire E, Bouchard P, Field M, Jones K, Lorenz B, Menten B, Buysse K, Pattyn F, Friedli M, Ucla C, Rossier C, Wyss C, Speleman F, De Paepe A, Dekker J, Antonarakis SE, De Baere E: Disease-causing 7.4 kb cis-regulatory deletion disrupting conserved non-coding sequences and their interaction with the FOXL2 promotor: implications for mutation screening. PLoS Genet 2009;5:e1000522.
31.
Li WX, Wang XK, Sun Y, Wang YL, Lin LX, Tang SJ: A novel mutation in the FOXL2 gene in a Chinese family with blepharophimosis, ptosis, and epicanthus inversus syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005;22:372-375.
32.
Qian X, Shu A, Qin W, Xing Q, Gao J, Yang J, Feng G, He L: A novel insertion mutation in the FOXL2 gene is detected in a big Chinese family with blepharophimosis-ptosis-epicanthus inversus. Mutat Res 2004;554:19-22.
33.
Gijsbers AC, D'Haene B, Hilhorst-Hofstee Y, Mannens M, Albrecht B, Seidel J, Witt DR, Maisenbacher MK, Loeys B, van Essen T, Bakker E, Hennekam R, Breuning MH, De Baere E, Ruivenkamp CA: Identification of copy number variants associated with BPES-like phenotypes. Hum Genet 2008;124:489-498.
34.
De Baere E, Lemercier B, Christin-Maitre S, Durval D, Messiaen L, Fellous M, Veitia R: FOXL2 mutation screening in a large panel of POF patients and XX males. J Med Genet 2002;39:e43.
35.
Harris SE, Chand AL, Winship IM, Gersak K, Aittomaki K, Shelling AN: Identification of novel mutations in FOXL2 associated with premature ovarian failure. Mol Hum Reprod 2002;8:729-733.
36.
Bodega B, Porta C, Crosignani PG, Ginelli E, Marozzi A: Mutations in the coding region of the FOXL2 gene are not a major cause of idiopathic premature ovarian failure. Mol Hum Reprod 2004;10:555-557.
37.
Ni F, Wen Q, Wang B, Zhou S, Wang J, Mu Y, Ma X, Cao Y: Mutation analysis of FOXL2 gene in Chinese patients with premature ovarian failure. Gynecol Endocrinol 2010;26:246-249.
38.
Laissue P, Lakhal B, Benayoun BA, Dipietromaria A, Braham R, Elghezal H, Philibert P, Saad A, Sultan C, Fellous M, Veitia RA: Functional evidence implicating FOXL2 in non-syndromic premature ovarian failure and in the regulation of the transcription factor OSR2. J Med Genet 2009;46:455-457.
39.
Gersak K, Harris SE, Smale WJ, Shelling AN: A novel 30 bp deletion in the foxl2 gene in a phenotypically normal woman with primary amenorrhoea: case report. Hum Reprod 2004;19:2767-2770.
40.
Chatterjee S, Modi D, Maitra A, Kadam S, Patel Z, Gokrall J, Meherji P: Screening for FOXL2 gene mutations in women with premature ovarian failure: an Indian experience. Reprod Biomed Online 2007;15:554-560.
41.
Geetha P, Nair MK: Granulosa cell tumours of the ovary. Aust NZ J Obstet Gynaecol 2010;50:216-220.
42.
Schumer ST, Cannistra SA: Granulosa cell tumor of the ovary. J Clin Oncol 2003;21:1180-1189.
43.
Shah SP, Kobel M, Senz J, et al: Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009;360:2719-2729.
44.
Benayoun BA, Caburet S, Dipietromaria A, Georges A, D'Haene B, Pandaranayaka PJ, L'Hote D, Todeschini AL, Krishnaswamy S, Fellous M, De Baere E, Veitia RA: Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134trp (c.402c>g). PLoS One 2010;5:e8789.
45.
Schrader KA, Gorbatcheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, Maines-Bandiera S, Cooke SL, Leung P, Brenton JD, Gilks CB, Monahan J, Huntsman DG: The specificity of the FOXL2 c.402c>g somatic mutation: a survey of solid tumors. PLoS One 2009;4:e7988.
46.
Jamieson S, Butzow R, Andersson N, Alexiadis M, Unkila-Kallio L, Heikinheimo M, Fuller PJ, Anttonen M: The FOXL2 c134w mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol 2010;23:1477-1485.
47.
Kim JH, Yoon S, Park M, Park HO, Ko JJ, Lee K, Bae J: Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (c134w). Oncogene 2011;30:1653-1663.
48.
Kim MS, Hur SY, Yoo NJ, Lee SH: Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J Pathol 2010;221:147-152.
49.
Hes O, Vanecek T, Petersson F, Grossmann P, Hora M, Perez Montiel DM, Steiner P, Dvorak M, Michal M: Mutational analysis (c.402c>g) of the FOXL2 gene and immunohistochemical expression of the FOXL2 protein in testicular adult type granulosa cell tumors and incompletely differentiated sex cord stromal tumors. Appl Immunohistochem Mol Morphol 2011;19:347-351.
50.
Al-Agha OM, Huwait HF, Chow C, Yang W, Senz J, Kalloger SE, Huntsman DG, Young RH, Gilks CB: FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol 2011;35:484-494.
51.
D'Angelo E, Mozos A, Nakayama D, Espinosa I, Catasus L, Munoz J, Prat J: Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod Pathol 2011;24:1360-1367.
52.
Gershon R, Aviel-Ronen S, Korach J, Daniel-Carmi V, Avivi C, Bar-Ilan D, Barshack I, Meirow D, Ben-Baruch G, Cohen Y: FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. Gynecol Oncol 2011;122:580-584.
53.
Fleming NI, Knower KC, Lazarus KA, Fuller PJ, Simpson ER, Clyne CD: Aromatase is a direct target of FOXL2:C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. PLoS One 2010;5:e14389.
54.
Benayoun BA, Georges AB, L'Hote D, Andersson N, Dipietromaria A, Todeschini AL, Caburet S, Bazin C, Anttonen M, Veitia RA: Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase. Hum Mol Genet 2011;20:1673-1686.
55.
Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC, Treier M: The murine winged-helix transcription factor FOXL2 is required for granulosa cell differentiation and ovary maintenance. Development 2004;131:933-942.
56.
Uda M, Ottolenghi C, Crisponi L, Garcia JE, Deiana M, Kimber W, Forabosco A, Cao A, Schlessinger D, Pilia G: FOXL2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. Hum Mol Genet 2004;13:1171-1181.
57.
Pailhoux E, Vigier B, Chaffaux S, Servel N, Taourit S, Furet JP, Fellous M, Grosclaude F, Cribiu EP, Cotinot C, Vaiman D: A 11.7-kb deletion triggers intersexuality and polledness in goats. Nat Genet 2001;29:453-458.
58.
Ottolenghi C, Omari S, Garcia-Ortiz JE, Uda M, Crisponi L, Forabosco A, Pilia G, Schles-singer D: FOXL2 is required for commitment to ovary differentiation. Hum Mol Genet 2005;14:2053-2062.
59.
Ottolenghi C, Pelosi E, Tran J, Colombino M, Douglass E, Nedorezov T, Cao A, Forabosco A, Schlessinger D: Loss of WNT4 and FOXL2 leads to female-to-male sex reversal extending to germ cells. Hum Mol Genet 2007;16:2795-2804.
60.
Uhlenhaut NH, Jakob S, Anlag K, Eisen-berger T, Sekido R, Kress J, Treier AC, Klugmann C, Klasen C, Holter NI, Riethmacher D, Schutz G, Cooney AJ, Lovell-Badge R, Treier M: Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell 2009;139:1130-1142.
61.
Murphy BD: Revisiting reproduction: what a difference a gene makes. Nat Med 2010;16:527-529.
62.
Kaur I, Hussain A, Naik MN, Murthy R, Honavar SG: Mutation spectrum of fork-head transcriptional factor gene (FOXL2) in Indian blepharophimosis ptosis epicanthus inversus syndrome (BPES) patients. Br J Ophthalmol 2011;95:881-886.
63.
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R: Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219-231.
64.
Rodin DA, Bano G, Bland JM, Taylor K, Nussey SS: Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 1998;49:91-99.
65.
Marneros AG, Krieg T: Keloids - clinical diagnosis, pathogenesis, and treatment options. J German Soc Dermatol JDDG 2004;2:905-913.
66.
Nakashima M, Chung S, Takahashi A, Kamatani N, Kawaguchi T, Tsunoda T, Hosono N, Kubo M, Nakamura Y, Zembutsu H: A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population. Nat Genet 2010;42:768-771.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.